{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:19:00Z","timestamp":1790713140764,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Daptomycin (DAP) is a key drug for treating severe <jats:italic toggle=\"yes\">Staphylococcus<\/jats:italic> infections. The emergence of DAP non-susceptible <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic> has been widely recognized in clinical situations, although the clinical status of DAP non-susceptible coagulase-negative <jats:italic toggle=\"yes\">Staphylococcus<\/jats:italic> (CoNS) infections is unclear. We encountered 2 cases of cardiovascular device infections that were associated with DAP non-susceptible CoNS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The first case involved a 60-year-old woman with a pump pocket infection in a left ventricular assist device. DAP non-susceptible <jats:italic toggle=\"yes\">Staphylococcus capitis<\/jats:italic> subsp<jats:italic toggle=\"yes\">. ureolyticus<\/jats:italic> was isolated from a blood culture after treatment using vancomycin (10 days) and DAP (6 days). The second case involved a 71-year-old man with an aortic graft infection. DAP non-susceptible <jats:italic toggle=\"yes\">S capitis<\/jats:italic> subsp<jats:italic toggle=\"yes\">. ureolyticus<\/jats:italic> was detected in pus after treatment using vancomycin (2 weeks) and DAP (1 week) without complete removal and debridement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Cardiovascular device infections caused by DAP non-susceptible CoNS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and outcomes:<\/jats:title>\n            <jats:p>Whole genome sequencing of these strains revealed multiple mutations in genes that are related to DAP-non-susceptibility in <jats:italic toggle=\"yes\">S aureus<\/jats:italic>, which created amino acid substitutions in <jats:italic toggle=\"yes\">mprF, dltAB, dltD, rpoC, yycG, cls2, pgsA<\/jats:italic>, and <jats:italic toggle=\"yes\">vraSR.<\/jats:italic> To the very best of our knowledge, the substitution patterns were not identical to those previously reported in DAP non-susceptibile <jats:italic toggle=\"yes\">S aureus.<\/jats:italic>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Clinicians should be cautious regarding the emergence of DAP non-susceptible CoNS, especially in cases with implanted prosthetic devices, inadequate debridement, and prior usage of vancomycin and DAP. Further studies are needed to understand the relevance of these genetic changes and DAP-non-susceptibility in CoNS strains.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013487","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T18:09:10Z","timestamp":1544292550000},"page":"e13487","source":"Crossref","is-referenced-by-count":9,"title":["Emergence of daptomycin non-susceptible coagulase-negative Staphylococci in patients with cardiovascular device infections"],"prefix":"10.1097","volume":"97","author":[{"given":"Hideharu","family":"Hagiya","sequence":"first","affiliation":[{"name":"Division of Infection Control and Prevention, Osaka University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Japan-Thailand Research Collaboration Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Kimura","sequence":"additional","affiliation":[{"name":"Laboratory for Clinical Investigation, Osaka University Hospital, Osaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Division of Infection Control and Prevention, Osaka University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Nishi","sequence":"additional","affiliation":[{"name":"Laboratory for Clinical Investigation, Osaka University Hospital, Osaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Center for Conservation of Microbial Genetic Resource, Gifu University, Gifu, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Akeda","sequence":"additional","affiliation":[{"name":"Division of Infection Control and Prevention, Osaka University Hospital"},{"name":"Japan-Thailand Research Collaboration Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Tomono","sequence":"additional","affiliation":[{"name":"Division of Infection Control and Prevention, Osaka University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240524","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R2-20240524","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/jac\/dkm091","article-title":"Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function","volume":"59","author":"Rose","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R3-20240524","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-20240524","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.diagmicrobio.2011.02.008","article-title":"Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010)","volume":"70","author":"Sader","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R5-20240524","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijantimicag.2006.05.030","article-title":"Mechanisms of daptomycin resistance in Staphylococcus aureus","volume":"28","author":"Kaatz","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"R6-20240524","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.diagmicrobio.2012.02.005","article-title":"Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus","volume":"73","author":"Sader","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R7-20240524","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(02)00438-3","article-title":"Pathogenesis of infections due to coagulase-negative staphylococci","volume":"2","author":"von Eiff","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"R8-20240524","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1086\/323676","article-title":"Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study","volume":"33","author":"Tacconelli","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R9-20240524","doi-asserted-by":"crossref","first-page":"e0184720","DOI":"10.1371\/journal.pone.0184720","article-title":"Genetic characterization of blaNDM-harboring plasmids in carbapenem-resistant Escherichia coli from Myanmar","volume":"12","author":"Sugawara","year":"2017","journal-title":"PLoS One"},{"key":"R10-20240524","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1099\/ijsem.0.001755","article-title":"Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies","volume":"67","author":"Yoon","year":"2017","journal-title":"Int J Syst Evol Microbiol"},{"key":"R11-20240524","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-013-0021-7","article-title":"Evaluation of daptomycin non-susceptible Staphylococcus aureus for stability, population profiles, mprF mutations, and daptomycin activity","volume":"2","author":"Steed","year":"2013","journal-title":"Infect Dis Ther"},{"key":"R12-20240524","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1128\/AAC.00432-10","article-title":"VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus","volume":"56","author":"Mehta","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20240524","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.00039-06","article-title":"Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus","volume":"50","author":"Friedman","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20240524","doi-asserted-by":"crossref","first-page":"e28316","DOI":"10.1371\/journal.pone.0028316","article-title":"Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus","volume":"7","author":"Peleg","year":"2012","journal-title":"PLoS One"},{"key":"R17-20240524","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.00202-07","article-title":"Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF","volume":"51","author":"Pillai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20240524","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1473-3099(09)70200-2","article-title":"Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions","volume":"9","author":"Moise","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R19-20240524","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R20-20240524","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09687688.2011.640948","article-title":"LC-MS\/MS characterization of phospholipid content in daptomycin-susceptible and-resistant isolates of Staphylococcus aureus with mutations in mprF","volume":"29","author":"Rubio","year":"2012","journal-title":"Mol Membr Biol"},{"key":"R21-20240524","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20240524","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13099-014-0045-x","article-title":"Whole genome sequence and comparative genomic analysis of multidrug-resistant Staphylococcus capitis subsp. urealyticus strain LNZR-1","volume":"6","author":"Li","year":"2014","journal-title":"Gut Pathog"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812070-00077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:03:15Z","timestamp":1716584595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812070-00077"}},"subtitle":["Two cases report investigated by whole genome analysis"],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":20,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013487","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}